Lucas Pinheiro Coutinho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lucas Pinheiro Coutinho has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Norberto de Kássio Vieira Monteiro
Universidade Federal do Ceará
2 shared publications - Aline Melro Murad
Laboratory of Mass Spectometry-LEM, Embrapa Genetic Resources and Biotechnology, Brasília, Brazil
1 shared publication - Amanda Fernandes de Medeiros
Biochemistry and Molecular Biology Postgraduate Program, Biosciences Center, Federal University of Rio Grande do Norte, Natal 59064-741, RN, Brazil
1 shared publication - Ana Heloneida de Araújo Morais
Federal University of Rio Grande do Norte
1 shared publication - Beatriz Blenda Pinheiro de Souza
Postgraduate Biological Molecular, Institute of Biological Sciences, University of Brasília, Brasília, Brazil
1 shared publication - Bruna Leal Lima Maciel
Graduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil
1 shared publication
Latest Publications
- 21 August 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 678, 148-157
A mechanistic insight for the biosynthesis of N,N-dimethyltryptamine: An ONIOM theoretical approach
- 21 August 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 678, 148-157
A mechanistic insight for the biosynthesis of N,N-dimethyltryptamine: An ONIOM theoretical approach
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 36 (1) , 480-490
Structural insights and molecular dynamics into the inhibitory mechanism of a Kunitz-type trypsin inhibitor from Tamarindus indica L
Trypsin inhibitors from tamarind seed have been studied in vitro and in preclinical studies for the treatment of obesity, its complications and associated comorbidities. It is still necessary to fully understand the structure and behaviour of these molecules. We purifed this inhibitor, sequenced de novo by MALDI-TOF/TOF, performed its homology modelling, and assessed the interaction with the trypsin enzyme through molecular dynamics (MD) simulation under physiological conditions. We identified additional 75 amino acid residues, reaching approximately 72% of total coverage. The four best conformations of the best homology modelling were submitted to the MD. The conformation n°287 was selected considering the RMSD analysis and interaction energy (–301.0128 kcal.mol−1). Residues Ile (54), Pro (57), Arg (59), Arg (63), and Glu (78) of pTTI presented the highest interactions with trypsin, and arginine residues were mainly involved in its binding mechanism. The results favour bioprospecting of this protein for pharmaceutical health applications.
- 1 January 2021
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 36 (1) , 480-490
Open AccessStructural insights and molecular dynamics into the inhibitory mechanism of a Kunitz-type trypsin inhibitor from Tamarindus indica L
Trypsin inhibitors from tamarind seed have been studied in vitro and in preclinical studies for the treatment of obesity, its complications and associated comorbidities. It is still necessary to fully understand the structure and behaviour of these molecules. We purifed this inhibitor, sequenced de novo by MALDI-TOF/TOF, performed its homology modelling, and assessed the interaction with the trypsin enzyme through molecular dynamics (MD) simulation under physiological conditions. We identified additional 75 amino acid residues, reaching approximately 72% of total coverage. The four best conformations of the best homology modelling were submitted to the MD. The conformation n°287 was selected considering the RMSD analysis and interaction energy (–301.0128 kcal.mol−1). Residues Ile (54), Pro (57), Arg (59), Arg (63), and Glu (78) of pTTI presented the highest interactions with trypsin, and arginine residues were mainly involved in its binding mechanism. The results favour bioprospecting of this protein for pharmaceutical health applications.